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Accumulation of prion protein in tonsil and appendix:
review of tissue samples
David A Hilton, Azra C Ghani, Lisa Conyers, Philip Edwards, Linda McCardle, Mark Penney,
Diane Ritchie, James W Ironside
Variant Creutzfeldt›Jakob disease is almost certainly
caused by the bovine spongiform encephalopathy
agent, and although the disease is rare (115 deaths to
date) there is uncertainty about future numbers of cases.1
The lack of a conventional immune response and the
inability to detect abnormal prion protein in blood has
hampered the development of a blood test.1 Lympho›
reticular accumulation of prion protein has been used as
a preclinical test for scrapie (the form of the disease in
sheep and goats) and is a consistent feature of variant
Creutzfeldt›Jakob disease, occurring before the onset of
symptoms.2–4 We screened large numbers of specimens
from appendicectomies and tonsillectomies for the
presence of prion protein in lymphoreticular tissue to
determine the number of people with preclinical variant
Creutzfeldt›Jakob disease.
Methods and results
We retrieved appendix and tonsil samples removed
between 1995 and 1999 from patients aged 10›50 from
histopathology departments across the United King›
dom. The samples were anonymised before testing. We
also examined appendix samples removed at autopsy or
at surgery from patients with variant Creutzfeldt›Jakob
disease. Prion protein was detected by immunohisto›
chemistry with monoclonal antibodies 3F4 (Dako, Ely,
Cambridge) and KG9 (Institute for Animal Health,
Newbury) and visualised with the catalysed signal ampli›
fication system (Dako). We excluded cases with fewer
than five secondary lymphoid follicles from the final
analyses because in the previously reported case and
those examined at autopsy, prion protein was present in
around 20% of follicles.4 We tested 11 228 samples, of
which 2910 were excluded. Most samples were
appendixes and 70% were from patients aged 20›29. In
one case we identified prion protein immunoreactivity
in a single lymphoid follicle stained with KG9 (figure).
The pattern of staining was similar to that seen in the
two other patients who developed variant Creutfeldt›
Jakob disease (figure1).4 This positive staining was less
evident in sections stained with 3F4 antibody. The
reason for this discrepancy is not clear but may be due to
sampling error because of the focal nature of prion pro›
tein deposition. In the appendixes removed before the
onset of symptoms in three patients with variant
Creutfeldt›Jakob disease, two (removed in 1995 and
1996; see figure) were positive, and the third (removed in
1987) was negative.4 Overall, 19 of 20 appendixes
removed at autopsy from cases of variant Creutzfeldt›
Jakob disease with adequate numbers of lymphoid folli›
cles had lymphoreticular accumulation of prion protein.
Comment
One appendix showing the lymphoreticular accumula›
tion of prion protein out of 8318 samples tested gives
an estimated detectable prevalence of prion protein
accumulation of 120 per million (95% confidence
interval, 0.5 to 900) among people aged 10›50 between
1995 and 1999. Our study design precluded transmis›
sion studies, but the accumulation of prion protein in
lymphoreticular tissue detected by the immunohisto›
chemical technique correlates with the detection of
abnormal prion protein by western blotting and
remains the only technique shown to reliably predict
disease in animals.2 3 5 The sensitivity and specificity of
preclinical lymphoreticular accumulation of prion
protein in predicting variant Creutzfeldt›Jakob disease
are unknown, but in sheep exposed to scrapie are esti›
mated to be 87% and 94%, respectively.5 At autopsy,
95% of appendixes from patients with variant
Creutzfeldt›Jakob disease with adequate amounts of
lymphoid tissue showed accumulation of prion
protein, as did both appendixes removed during the
1990s from patients who later developed the disease.
We provide the first estimate of the number of
people who may be a potential source of variant
Creutzfeldt›Jakob disease by iatrogenic spread. Large
scale prospective screening of tissue from tonsillecto›
mies is needed to obtain precise data on prevalence.
The use of fresh tissue would allow for a semi›
automated western blot assay and verification of
positive samples by transmission studies. As half of
tonsillectomies are in children under 10, who will have
had little or no exposure to bovine spongiform
encephalopathy, the opportunity for such a study will
diminish over time.
We thank histopathology departments and relatives of patients
with variant Creutzfeldt›Jakob disease who gave consent for
autopsy tissues to be used as positive control material.
Contributors: DAH designed the English study, screened
samples tested at Plymouth, and drafted the manuscript; he will
act as guarantor for the paper. JWI designed the Scottish study,
screened samples tested at Edinburgh, and contributed to the
manuscript. ACG performed the statistical analyses and
contributed to the manuscript. MP, LC, and PE performed the
technical work at Plymouth. LMcC and DR performed the tech›
nical work and assisted in screening samples at Edinburgh.
(Left) Distribution of coarse granular prion protein within lymphoid follicle of appendix,
suggestive of follicular dendritic cells. (Right) Lymphoreticular accumulation of prion protein
in appendix tissue from patient with Creutzfeldt›Jakob disease, removed two years before
onset of symptoms
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Informed consent for genetic research on blood stored for
more than a decade: a population based study
Birgitta Stegmayr, Kjell Asplund
With recent advances in molecular genetics, there has
been a surge in interest in using stored blood samples
for genetic research, even though informed consent at
the time of blood sampling did not include this possi›
bility. One of the cornerstones of the World Medical
Association’s Declaration of Helsinki on ethical princi›
ples for medical research is the need for informed con›
sent and the right of any participant in a research
project to withdraw at any time.1 We report here our
experiences of seeking informed consent for academic
and commercial genetic research on blood samples
collected more than a decade earlier.
Methods and results
A total of 1583 out of 2000 (79.2%) randomly selected
men and women in the age group 25›64 years
participated in the 1990 risk factor survey in the World
Health Organization’s MONICA project.2 3 Participants
were given written information and asked to donate
blood for “future research on cardiovascular disorders
and diabetes.” A total of 1494 blood samples were taken
(in 89 participants, consent was not given or technical
problems arose in obtaining a blood sample). The blood
samples were fractionated and stored at –80° C.
In 2001, 11 years later, 85 of the 1494 individuals
had died, moved abroad, or had an unknown address
(figure). We sent a letter to the remaining 1409 partici›
pants with information about ongoing genetic studies
and seeking consent at three different levels (figure). Of
the 1409 subjects, 1342 (95.2%) responded.
A total of 1311 out of 1409 (93.0%) eligible partici›
pants gave their consent for their blood samples to be
used for academic genetic research, provided that the
ethics committee had approved the research. Thirty
one (2.2%) participants did not give their consent; 64
participants did not reply and three provided
incomplete answers (4.8% together).
Of the 1311 participants who gave their consent,
292 (22.3%) wanted to be informed about, and give new
consent for, each new genetic project (figure). The rest
gave general consent to genetic research, as long as an
ethics committee had approved the research. However, a
further 35 (2.5%) participants did not give consent for
their blood to be used for industrial genetic research
(figure).
Comment
Eleven years after donation of samples, only a very
small proportion of participants did not give consent
for their blood to be used in academic or industrial
genetic research.
To our knowledge, this report is the first to provide
empirical data from a “real life” situation—that is,
people’s willingness to give consent to genetic research
on their own blood donated more than a decade previ›
ously, when genetic research was not an issue. Participa›
tion in risk factor screening is, in itself, an expression of
willingness to contribute to research. The participants in
the original survey in 1990 were randomly selected, with
a participation rate as high as 79%, thus suggesting that
1990: participants in MONICA project
(n = 1583)
Initial consent given and 
blood sample donated
(n = 1494)
By 2001:
• 63 had died
• 13 had moved abroad
• 9 had unknown addresses
2001: questionnaire sent 
to eligible individuals
(n = 1409)
No (n = 31) Yes (n = 1311)
Yes (n = 1276) No (n = 66)
No (n = 292) Yes (n = 1019)
Do you give your consent
that the blood samples you
donated in the health survey
in  1990 may be used for 
academic research on 
hereditary (genetic research) 
of cardiovascular diseases, 
provided that the ethics 
committee has given approval?
No response or 
incomplete response
(n = 67)
Do you want to be contacted 
before every new research 
project in which your blood 
sample is intended to be used?
Do you give your consent that the 
blood samples you donated may 
be used for industrial research on 
heredity (genetic research) of 
cardiovascular diseases, provided 
that the ethics committee has 
given approval and the samples 
are anonymised? 
Follow up in 2001 of participants in 1990 MONICA survey, showing numbers of participants
lost to follow up and responses to questionnaire about consent for blood to be used in
genetic research
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